This Dividend King Just Offered a Buy-the-Dip Opportunity
Deal skepticism and litigation fears still weigh on this consumer staples stalwart.
Yahoo4 days agoKVUE
Kimberly Clark (KMB) Names New Legal Chief As Kenvue Deal Puts Valuation In Focus
Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...
Yahoo8 days agoKVUE
Pure Strategies Announces "Day of Action" Full Day Program during Climate Week NYC - September 23, 2026
Pure Strategies, a sustainability consulting firm empowering brands and retailers to realize meaningful environmental and social improvement, is offering a full day of workshops, panels, and small group discussions during Climate Week NYC. The "Day of Action" program, being held Wednesday, September 23, 2026, is designed to help companies advance climate and nature strategies and turn sustainability investment into measurable returns.
Yahoo8 days agoKVUE
Kenvue Deserves Some Love As Its Purchase By Kimberly-Clark Looks Imminent
Kenvue Inc. upgraded to a soft buy as the Kimberly-Clark Corporation merger looks likely. Click for this updated look at KVUE and KMB as they seek to join.
SeekingAlpha10 days agoKVUE
National Advertising Division Finds Hims & Hers Has Support for Combination Efficacy Message; Recommends Modification or Discontinuance of Other Claims
In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National Advertising Division (NAD) recommended that it modify or discontinue other claims regarding doctor-trusted ingredients, dermatologist recommendations, safety and side effects.New York, NY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Kenvue Inc., BBB National Progra
Yahoo10 days agoKVUE
Kenvue: Acquisition By Kimberly-Clark Hit An Obstacle - What Now
Kenvue Inc.âs KMB buyout faces China SAMR Phase 2 antitrust review. Click for more on KVUE and how this affects whether you should invest in KVUE stock.
SeekingAlpha11 days agoKVUE
Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings
Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...
Yahoo14 days agoKVUE
Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?
In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...
Yahoo14 days agoKVUE
Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future
Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.
Yahoo15 days agoKVUE
Will a Neutrogena boycott by Hayden Panettiere's fans work?
Panettiere's death has re-ignited calls to boycott Neutrogena, which she said ended a partnership after she spoke out about postpartum depression.
Yahoo15 days agoKVUE
Kenvue (KVUE) Launches Zyrtec Spray As Its Undervalued Case Faces A Fresh Test
Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...
Yahoo15 days agoKVUE
Essity acquires feminine care business in Brazil
Hygiene and health company Essity has entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The purchase price amounts to USD 284m (approximately SEK 2.7bn) on a cash and debt-free basis. The acquisition strengthens Essity's position as a market leader in feminine care in Latin America.
Yahoo15 days agoKVUE
Essity Strikes Agreement To Acquire Kenvue's Feminine Care Operations In Brazil For $284M
https://www.essity.com/media/press-release/essity-acquires-feminine-care-business-in-brazil/9dd724cebbb532f5/
Benzinga16 days agoKVUE
Jim Cramer Said Kimberly-Clark Corporation (NYSE:KMB) + Kenvue Could Take On P&G – But Is He Right?
Personal care products provider Kimberly-Clark Corporation (NYSE:KMB)’s shares are down by 17% over the past year and are up by 9% year-to-date. It is currently undergoing a major transformation through acquiring Kenvue. Cramer has discussed Kimberly-Clark Corporation (NYSE:KMB)’s acquisition several times and linked its performance with consumer goods giant Procter & Gamble. In his morning […]
Yahoo21 days agoKVUE
Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel
Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Jeff Melucci, Chief Strategy, Business Development and Administrative Officer, and will become a member of Kimberly-Clark's Executive Leadership Team.
Yahoo22 days agoKVUE
Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects
KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
Yahoo23 days agoKVUE
Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy
Kimberly-Clark looks good, supported by a strong innovation pipeline, international growth, and the Kenvue acquisition. See why I rate KMB stock a Buy.
SeekingAlpha23 days agoKVUE
UBS Maintains Neutral on Kenvue, Lowers Price Target to $19
UBS analyst Peter Grom maintains Kenvue (NYSE:KVUE) with a Neutral and lowers the price target from $20 to $19.
Benzinga24 days agoKVUE
Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong'
President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11 vaccines.
Benzinga24 days agoKVUE
How Reddit and Wall Street See Kenvue as Buyout Nears
Kenvue just snapped a four-quarter earnings streak while Reddit falls nearly silent, and the reason why tells you everything about where this stock goes next.
Yahoo28 days agoKVUE